Clinical Trial Update: A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of amlenetug (Lu AF82422) in participants with Multiple System Atrophy is active-not-recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• Amlenetug (Lu AF82422) (amlenetug)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Multiple System Atrophy | Phase 3 | Status: ACTIVE_NOT_RECRUITING